Troglitazone

Thiazolidinedione; PPARγ agonist, ATP-sensitive K+ channel blocker.



LKT-T7056-M010	10 mg	103.00 USD

LKT-T7056-M050	50 mg	397.00 USD

LKT-T7056-M100	100 mg	587.00 USD

A novel antidiabetic agent. It is found to exert significant cell cycle arrest and apoptosis in hepatocellular carcinoma cell lines. It has a unique property of selectively inducing EGR-1 gene independent of PPARγ. Potential preventive agent for colon carcinogenesis.

PRODUCT PROPERTIES
Formula:		C₂₄H₂₇NO₅S
MW:		441.54
CAS:		97322-87-7
MI:		13: 9838
Purity:		≥97%
Solubility:		Soluble in DMSO 15mg/mL, and dimethyl formide. Slightly soluble in 100% ethanol (warm).
Long Term Storage:		Ambient

Formula:

TECHNICAL DOCUMENTS Print as PDF	RELATED PRODUCTS No related products available
PRODUCT SUPPORT Technical Service Bulk Quantity Quote Customer Service	CATALOG SECTION Apoptosis Inducers & Inhibitors Oth... Peroxisome Proliferator Activated-R... Peroxisome Proliferator Activated-R... Peroxisome Proliferator Activated-R... Antidiabetic Agents

Product Literature References

Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice: E. Osawa, et al.; Gastroenterology 124, 361 (2003), Abstract;

Troglitazone and related compounds: therapeutic potential beyond diabetes: T. Fujiwara and H. Horikoshi; Life Sci. 67, 2405 (2000), Abstract;

Troglitazone

TECHNICAL DOCUMENTS

RELATED PRODUCTS

PRODUCT SUPPORT

CATALOG SECTION

Product Literature References